COMPASS Pathways plc
Healthcare / Medical Care Facilities
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Performance
--
Today 0.00 (0.00%)
CMPS
Metrics
Market Cap2.1B
Latest Price$14.28
Previous Close$13.80
Volume1.6M
52 Week High$15.40
52 Week Low$4.82
52 Week Change178.02%
Average Volume3.3M
Revenue0
EPS-3.79
P/E Ratio0
Forward P/E-10.413
Price/Book23.957
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-3.19%
Dividend Yield0.00%